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A large number of chemicals may exert adverse effects on the central and/or peripheral nervous
system. A commonly recommended strategy for neurotoxicity testing is that of a tiered approach
aimed at identifying and characterizing the neurotoxicity of a compound. Guidelines exist in the
United States and other countries that define the tests to be utilized in tier 1 testing. To address
problems related to the increasing cost and time required for toxicity testing, the increasing
number of chemicals being developed, and the concern of animal welfare activists, attention is
currently being devoted to in vitro alternatives. This paper addresses the use of in vitro systems
in neurotoxicology, and their potential role in a general strategy for neurotoxicity testing. The
advantages and disadvantages of in vitroapproaches for mechanistic studies and for screening of
neurotoxicants are discussed. Suggestions for further validation studies are proposed. Environ
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Introduction
The nervous system is one of the most
complex organ systems in terms ofboth
structure and function. Nerve cells are
unique in that they are not capable ofregen-
eration after lethal damage, thus rendering
the nervous system particularlyvulnerable to
toxic insult (1,2). Neurotoxicity is defined
as "any adverse effect on the chemistry,
structure and function ofthe nervous sys-
tem during development or at maturity,
induced by chemical or physical influences"
(3). The key issue is the interpretation ofthe
word adverse, as there is not always agree-
ment among scientists on what constitutes
an adversechange. Issues thathavebeen con-
sidered include the nature ofthe change
(morphologic, neurochemical, neurologic,
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or behavioral), the degree ofchange, and
whether the effect is transitory or persistent.
A proposed definition ofan adverse effect is
"any treatment-related change which inter-
feres with normal function and compro-
mises adaptation to the environment" (4).
Most morphologic changes such as neu-
ronopathy, axonopathy, or myelinopathy
would be considered adverse, even ifthe
changes were mild or transitory. On the
other hand, a transitory hypertrophy of
astrocytes could be viewed as an adaptive,
physiologic response (4). However, one
could argue that such an adaptive response
may reflect prior damage to neuronal struc-
tures, and thus be a relevant biomarker ofan
adverse effect. Furthermore, a still-debated
issue is whether neurochemical effects in
the absence ofstructural damage should be
considered adverse. Certainly an acute
intoxication with an organophosphorus
insecticide produces acute neurotoxic
effects that tend to resolve with time.
Additionally, repeated exposure to these
compounds changes the homeostasis ofthe
cholinergic system, altering the response to
cholinergic drugs and possibly interfering
with cognitive processes (5). Similarly,
acute response to solvents may cause only
transient central nervous system effects, but
these should be considered neurotoxic as
they can lead to impaired function.
Another concept in neurotoxicity is the
difference between direct and indirect
effects on the nervous system. Damage to
hepatic, renal, or pancreatic structures can
result in secondary effects on the function
and structure ofthe nervous system, such
as encephalopathy or polyneuropathy.
Secondary effects would not cause a sub-
stance to be considered neurotoxic; how-
ever, atveryhigh doses, neurotoxicitywould
be evident. The identification ofneurotoxic
effects seen after administration of doses
that exceed the maximum tolerated dose, or
at which the normal metabolic processes of
the bodyare severelycompromised, is there-
fore a recognized problem (4). Thus, a sub-
stance should be defined as neurotoxic
when it or its metabolites produce adverse
effects as a result ofdirect interactions with
the nervous system. This paper briefly
reviews some current approaches and
methods of in vivo neurotoxicity testing
and their advantages and limitations. It
then analyzes the current efforts aimed at
implementing and validating in vitro
methodologies for such testing, and dis-
cusses the steps necessary for an integration
ofthe different approaches.
Detecting Neurotoxicity in
Standard ToxicityTesting
Standard toxicity studies, required by
national and international regulatory agen-
cies, involve exposure to a chemical on an
acute, subacute, subchronic, and chronic
basis, in addition to reproductive studies
and other studies (e.g., those for genotoxic-
ity). These studies are relevant in the
assessment of potential neurotoxicity, as
they are conducted at different dose levels,
with different routes and durations of
administration, in different animal species.
Data on metabolism and toxicokinetics are
also developed in support ofsuch studies.
These studies include clinical observations
and morphologic examinations, which can
reveal effects on the nervous system. These
may include changes in motor functions or
in autonomic functions, or damage to rele-
vant brain structures. It is important that
such studies are conducted carefully and
the observations documented precisely.
Clinical signs should be recorded as they
are observed, and should include time of
onset, degree, and duration of effects.
Parameters should include changes in skin,
fur, secretion, activity, gate, response to
stimuli, etc. Brain weight should be
recorded at autopsy. Histologic examina-
tion should include the brain, the spinal
cord, and one peripheral nerve. Examples
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ofchemicals whose neurotoxicity has been
identified in standard subchronic studies
include sulfuryl fluoride (6), tris(2-
chloroethyl)phosphate (7), and benzal-
dehyde (8). Ifthe dinical observations and
morphologic examination do not indicate
any evidence ofnervous system effects, and
when the chemical structure of the sub-
stance and/or its metabolites does not sug-
gest concern for potential neurotoxicity, the
substance can be considered as not neuro-
toxic. In this case, no further testing would
be warranted until any new cause for con-
cern for the nervous system may arise. If
standard toxicity studies ofa new chemical
provide evidence ofdirect, adverse effects
on the nervous system, its development for
use may be abandoned without further test-
ing (2). On the other hand, neurotoxicity
testing may be conducted for more com-
monly existing substances with commercial
value orwide exposure.
Testing for Neurotoxicity:
ATiered Approach
Because ofthe variety oftoxic effects and of
cellular biochemical targets, a test strategy
for the evaluation ofthe neurotoxic poten-
tial ofchemicals should not be totally rigid,
butshould be determined casebycase, with
an emphasis on the structure ofthe chemi-
cal and the indications ofthe standard toxi-
city tests. Though structure-activity
relationship studies are undoubtedly impor-
tant, caution should also be exerted, as
empirical findings can be unexpected and
unpredictable at times. Forexample, among
organic tin compounds only two-
trimethyltin and triethyltin-are neuro-
toxic, though their effects are notably
different, whereas other trisubstituted
compounds are not.
A commonly recommended strategy for
neurotoxicity testing is that of a tiered
approach consisting ofthree tiers aimed at
identifying (tier 1), and characterizing (tiers
2 and 3) the neurotoxicity ofa chemical
(2). Initial neurotoxicity studies should
thoroughly evaluate the nervous system
with a number ofbroad but system-specific
tests, to provide adequate data for risk
assessment. Because ofthe multiplicity of
possible effects on the nervous system, there
is no single test method that can ensure the
detection and identification ofevery possi-
ble change. The tests that are used are those
included in the guidelines of the U.S.
Environmental Protection Agency (U.S.
EPA) (9) and the Organisation for Eco-
nomic Co-operation and Development
(10). These include acute and subchronic
administrations ofthe tested chemical and
a number ofbehavioral observations, spe-
cific measurements, and neuropathologic
examinations (Table 1). The functional
observation battery is a standardized
screening battery for the assessment of
many aspects ofbehavior and neurologic
functions in rodents, and has been vali-
dated with several known neurotoxic
chemicals. Special tests are conducted to
identifyspecific deficits in motorand sensory
functions; these may include automated
measurements of motor activity, rotating
rods, landing footspread, measurements of
fore- and hindlimb strength, measurements
of auditory or thermal thresholds, and
measurements ofstartle reflex.
Histologic examination ofcentral and
peripheral nervous systems would include
as a minimum the following tissues: brain
(several sections including those structures
involved in specific types of behaviors),
spinal cord (including dorsal root gan-
glion and dorsal/ventral roots), and peri-
pheral nerves (sciatic and tibial nerves).
Measurement ofglial fibrillary acidic pro-
tein or similar approaches (e.g., involving
measurements ofneuronal-specific proteins
or microglial reactivity), would also provide
useful information on potential neurotoxic-
ity, particularly ifthe experimental design
provides for multiple measurements (29).
If there is no evidence of a nervous
system effect in tier 1 studies, then the sub-
stance can be considered as not neurotoxic.
When, however, persistent effects on the
nervous system are detected, the chemical
can be considered a probable human neuro-
toxicant. In such cases, additional tests may
be warranted in tier 2 and 3 studies to char-
acterize the neurotoxiceffects. The datafrom
tier 1 studies should provide the basis for
generation ofspecific hypotheses for subse-
quent studies and guide in the selection of
the appropriate methods. The decision to
carry out additional studies should be made
on a case-by-case approach, and maydepend
upon factors such as the intended use ofthe
chemical, the potential ofhuman exposure,
and its potential to accumulate in biological
systems. Such studies mayindudespecialized
behavioral tests, electrophysiologic and
neurochemical measurements, and additional
morphologic studies. Examples ofsuch
studies indude tests for measuring learning
and memory (active or passive avoidance,
spatial discrimination tasks); operant condi-
tioning with various schedules of nerve
conduction velocity; electromyography,
neurochemical tests (markers ofneuronal or
glial cells, biochemical parameters ofcell
Table 1. Summary ofthe U.S. EPAneurotoxicitytesting
guidelines.
Animals
Adult rats, male and female
Group size
10/sex/group
Control group
Vehicle control
Dose level
Acute exposure(3doses)
Subchronic exposure(3doses)
Route ofexposure
Considerhuman exposure kinetics
Observations
Convulsions, tremors, hyperactivity, aggression,
stereotypes, autonomicsigns, abnormal posture
orgait,activity level, abnormal respiration,
vocalization
Measurements
Bodyweight
Sensoryfunctions
Gripstrength
Motoractivity
Landing footsplay
Neuropathology
Insitufixation
Paraffin/plastic embedding
H&E stain
Additional stains if necessary
Tissues/sections
All majorregions of nervous system
(central and peripheral)
functions or integrity, biochemical parame-
ters related to neurotransmission and signal
transduction); measurement of2-deoxyglu-
cose accumulation; and analysis ofnerve tis-
sue after perfusion fixation (which may
include electron microscopy examinations
and use ofimmunohistochemical and mor-
phometric methods). These tests should
allow a thorough characterization ofthe
neurotoxicity ofa substance and provide
information on its mechanism ofaction.
Special Issues in
Neurotoxicity Testing
NeurotoxicityInducedby
Oranophosphorus Compounds
A number oforganophosphorus compounds
that have been used mostly as insecticides
have the ability to cause a particular neuro-
toxicityknown as organophosphate-induced
delayed neuropathy (OPIDN). OPIDN is
characterized as a distal-central peripheral
neuropathy and becomes apparent with a
delay of2 to 3 weeks after acute exposure.
Regulatory guidelines require that special-
ized neurotoxicity testing be conducted
with all compounds ofthis dass (9,10). The
compound is administered acutely and
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subchronically to adult hens and the even-
tual insurgence ofataxia and other clinical
signs are monitored and scored. Neuro-
pathologic examinations ofbrain, spinal
cord, and peripheral nerves are then carried
out. The U.S. EPA also requires biochemi-
cal measurement of the activity of an
enzyme, neuropathy target esterase, that is
considered the target for initiation ofthe
neuropathy. For several years, testing for
OPIDN has been theonlytype ofneurotox-
icity testing required by regulatory agencies,
and theprocess has been, for the most part,
successful in detecting compounds able to
cause delayed neurotoxicity and prevent
their commercialization. Recently, however,
neurotoxicity occurred in an individual who
had ingested an extremely high dose ofan
organophosphate (far exceeding the dose
used in animal studies) and was able to
survive the acute cholinergic poisoning.
DevelopmenUlNeurotoxicity
The nervous system undergoes gradual
development that continues well after birth
in both animals and humans. On one
hand, the developing nervous system can
more readily adapt to, or compensate for,
functional losses as a result oftoxic insult;
however, these may result in a delayed
functional development. On the other
hand, damage to the nervous system dur-
ing key periods ofbrain development may
result in long-term, irreversible damage.
The absence of a fully developed blood-
brain barrier may result in the accumula-
tion in the brain ofcertain chemicals in
greater quantities than in adults. Special
guidelines thus exist to determine develop-
mental neurotoxicity. In principle, care-
fully conducted reproductive studies
should be able to provide initial indications
ofpotential developmental neurotoxicity.
However, it has been shown that reliance
on, for example, the Chernoff/Kavlock ter-
atology assay as a primary developmental
neurotoxicity screen could lead to a num-
ber offalse negatives (30). Current devel-
opmental neurotoxicity screening (9)
includes a number of observations and
measurements aimed at determining the
development of proper motor sensory
functions, learning, and memory, together
with landmarks ofphysical development.
In VitroNeurotoxicityTesting
The need to develop acceptable alternatives
to conventional animal toxicity testing is
increasingly recognized by toxicologists,
to address problems related to the escalat-
ing costs and time required for toxicity
assessment, the increasing number of
chemicals being developed and commer-
cialized, and the concern ofanimal-welfare
activists (11,12). In the past several years, a
number of publications have addressed
issues related to the use of in vitro systems
for neurotoxicity testing; they are reviewed
here onlybriefly (11,13-18).
In vitro testing procedures have several
practical advantages; yet, the limitations of
such approaches should also be outlined,
particularly in the field ofneurotoxicology,
because ofthe complexity ofthe nervous
system. To date, in vitro systems have been
used extensively to study the mechanism of
action ofneurotoxic agents. However, their
use in hazard identification in human
health risk assessment has not been
explored to any great extent (19). Data
generated from in vitro procedures are
based on simplified approaches that require
less time and cost to yield information
(two clear advantages), but that do not take
into account the distribution ofthe toxi-
cant in the body, the route ofadministra-
tion, and the metabolism ofthe substance
(19). In addition, it is difficult to extrapo-
late in vitro toxicity data to animal or
human neurotoxicity end points such as
sensory disorders or cognitive impairment.
Several in vitro systems are currently being
evaluated for their ability to predict the
neurotoxicity ofvarious agents seen in
intact animals, and an important part of
this process should be the detection offalse
negatives. Until this process proves satisfac-
tory, a cautious view should be that out-
lined recently by the U.S. EPA in their
proposed guidelines for neurotoxicity risk
assessment: "Demonstrated neurotoxicity
in vitro in the absence of in vivo data is
suggestive but inadequate evidence of a
neurotoxic effect. On the other hand, in
vivo data supported by in vitro data
enhance the reliability of the in vivo
results" (19).
What are the advantages of in vitro
testing systems for neurotoxicity, and what
is their best utilization in neurotoxicology?
The savings in terms of time, costs, and
animal use have already been mentioned.
Other advantages ofin vitrotoxicity testing
are summarized as follows:
* Uniform chemical and physical envi-
ronment
* Toxic exposure continuous or inter-
mittent
* Exposure parameters strictlycontrolled
* Small amounts ofchemical needed
* Systemic (e.g., hepatic) effects bypassed
* Range ofdonor species available
* Human materials available (11)
Limitations of in vitro toxicity testing
are a) lack of integrated functions and
blood-brain barrier function; b) target
concentration not known; c) compensatory
mechanisms cannot be determined, and
d) single tests cannot cover all targets and
mechanisms (3).
Most in vitro systems for neurotoxicity
make use ofmammalian cells. In decreasing
order ofcomplexity, these models include
organotypic explants, brain slices, reaggre-
gate cultures, primary cell preparations, and
established cell lines. It should be noted that
with the exception ofcell lines all other
models involve the use ofcells or tissues
directly derived from animals. Thus, while
the number ofanimals may be reduced (as
in vitrosystems allow the testing ofmultiple
concentrations of chemicals and other
experimental manipulations in tissue
derived from a single animal), other prob-
lems inherent to the use ofprimary cell or
tissue cultures still necessitate the use ofa
substantial number ofanimals. From the
point ofview ofreducing the number of
animals, established cell lines are certainly
the system of choice. A benefit of using
organotypic explants, brain slices, or reag-
gregate cultures is that the cytoarchitecture
ofthe nervous system, the neural circuitryof
a specific brain area, or other biochemical
processes (e.g., myelination), are preserved.
Systems using primary cultures, on the
other hand, do not offer the retention of
neuronal circuitry but allow the study ofthe
effects of toxicants on separate cell types
(e.g., neurons, astrocytes, oligodendrocytes).
The latter results can also be achieved by the
use ofestablished cell lines. These have been
derived from tumors of mouse, rat, and
human, and are, for the most part, available
commercially. Cell lines are usually the sim-
plest to culture and many (e.g., several neu-
roblastoma or glioma cell lines or PC12
cells) have been extensively used in neurobi-
ologic studies, thus providing a large
amount ofinformation on their physiology
and biochemical composition. Further-
more, reproducibility ofresults is often bet-
ter in cell lines than in primary cultures.
On the other hand, cell lines are trans-
formed (tumor-derived) cells; thus, effects
in these cells may not always mimic those
occurring in untransformed cells.
In VitroSystemsfor
Mechanistic Studies
In vitro systems are amenable and very
useful for mechanistic studies at the cellular
and molecular level. As such, they have
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been extensively used in neurobiology and,
to a minor extent, in neurotoxicology.
Because ofthe variety ofnerve cells and the
complexity ofthe nervous system, no single
in vitro preparation can be relied on to
detect all possible end points (11,13).
Depending on the status ofknowledge on
the neurotoxicity ofa certain compound,
and of specific questions that are being
asked, different cellular systems or prepara-
tions can be used, and a tiered approach
can be applied in this context as well. For
example, neuroblastoma or glioma cell
lines can be used to investigate the interac-
tion ofneurotoxicants with ion channels or
receptor and signal transduction systems,
as well as with basic metabolic functions.
The hippocampal slice preparation can be
used to determine whether a chemical may
affect certain excitatory or inhibitory cir-
cuitries, as shown, for example, by a study
with trimethyltin (20). Primary cultures of
cortical, cerebellar. or hippocampal neu-
rons are being widely used to study mecha-
nisms of excitotoxicity (16); cultures of
Schwann cells may represent a good model
to study the effect ofchemicals on myeli-
nation. In vitro test systems are amenable
to biochemical, electrophysiologic, and
morphologic examinations. Molecular
biology approaches allow the study oftoxi-
cants on gene expression; techniques such
as transfection or the use of antisense
oligonucleotides allow the manipulation of
cells to address specific questions on the
role ofcertain genes, and proteins, in neu-
rotoxicity. The same caution as for any in
vitro test system, particularly when the
results are extrapolated to an in vivo situa-
tion, also applies to mechanistic studies.
For example, do the results obtained with a
cell line stably transfected with a certain
gene, apply to a different cell type where
the gene is expressed constitutively, per-
haps to a lesser degree? How does a phe-
nomenon such as neurite outgrowth differ
when investigated in vitro in pure neuronal
populations, from the in vivo situation,
where glial cells may directly and indirectly
play a most relevant role? Despite these
potential problems, in vitro systems are
extremely relevant from the point ofview
ofmechanistic neurotoxicology, and their
use is expected to increase.
In VitroSystems for
Neurotoxicity Screening
A goal of in vitro systems is that of
providing a quick and inexpensive way for
assessing potential neurotoxicity. Several
approaches have been proposed to identify
neurotoxicants and to distinguish them
from cytotoxicants, as well as to rank neu-
rotoxicants for toxic potency (11,13).
Screening is by definition a first-tier evalua-
tion ofchemicals that will be followed by
additional more specific and complex tests.
The same criteria for in vitro screening
approaches for other end points oftoxicity
also apply to the neurotoxicity screening;
they are a) low incidence offalse negatives
and false positives; b) high correlation with
in vivo toxicity data; and c) sensitive, sim-
ple, rapid, economical, and versatile. As
indicated by many scientists, the challenge
in developing in vitro systems for neuro-
toxicity is that ofdifferentiating cytotoxi-
cants from neurotoxicants. Because any cell
culture system poorly mimics the intact
nervous system, it is important to utilize a
variety ofin vitromodels and a multiplicity
ofend points to parallel, at least in part,
neurotoxicity in the whole animal (11).
Although the use ofa test battery is always
advocated and recommended, the choice of
the systems to be used has not yet been
defined, as various investigators have pro-
posed different though similar approaches
(14,18). A basic initial test battery should
include a neuronal and a glial cell line, pos-
siblyofhuman origin, one nonneuronal cell
line, and a slightly more complex system
such as the rat primary micromass (21) or
brain reaggregate cultures (11). Recently,
in vitro systems that could mimic the
blood-brain barrier, a potential target for
many neurotoxicants, have also been pro-
posed. They consist ofcocultures ofglial
cells and endothelial cells (or canine kidney
cells) and have been characterized, but not
yet sufficiently tested, for their suitability in
detecting neurotoxicants (22,23).
End points to be measured in in vitro
tests should include indicators ofcytotoxic-
ity and viability as well as neurotoxicity.
Basic tests ofcytotoxicity and viability are
common to most cell types and include
measurements ofcell death, membrane per-
meability, mitochondrial function, cell
growth and reproduction, energyregulation,
and synthesis ofmacromolecules. Ifthese
end points are affected by a chemical, one
cannot condude that the chemical is neuro-
toxic, but only that it displays cytotoxicity,
whose potency can be readily established by
conducting concentration-response experi-
ments. However, the use ofnonneuronal
cell types mayprovide initial information on
whether the chemical may have differential
effects ordisplay different potencies in nerve
versus nonnerve cells. For the screening of
putative neurotoxicants, neural-specific end
points representing neurochemical, neuro-
morphologic,and neurotransmission func-
tions are necessary (11,13). The choice of
such end points is not an easy task, as the
number of parameters that can be mea-
sured can be endless. This issue probably
represents the hardest problem to be sur-
mounted in order to implement the use of
in vitro systems as effective screening and
predictive tools. Among the biochemical
measurements that have been proposed are
assays for neurotransmitter synthesizing
enzymes (glutamic acid decarboxylase,
dopamine hydroxylase, choline acetyl-
transferase, tryosine hydroxylase), acetyl-
cholinesterase, neuron-specific enolase,
glutamine synthetase, and various neuro-
nal receptors, to mention only a few.
Morphologic end points such as neurite
extension can also be measured and quanti-
fied (24). If neurotoxicity end points are
affected at concentrations lower than those
producing cytotoxic effects, a chemical can
be considered a potential neurotoxicant.
The concern, however, remains that the
neurotoxic end points representing the tar-
get for a certain chemical may have been
missed by the assays chosen for the neuro-
toxicity screening, thus generating a false
negative result.
A number ofconsiderations should be
made with regard to potential problems
related to experimental design and techni-
cal aspects of in vitro neurotoxicity tests,
all ofwhich indicate the need for a strict
standardization of experimental proce-
dures. For example, the source and pas-
sage of the cell line, the cell density, the
effect ofsolvent, the source and composi-
tion of the media, and the duration of
exposure are all potential sources of error.
The fact that several chemicals must be
metabolized to active toxicants may be
good motivation to include microsomal
preparations (the S9 fraction) to the test
system, as is routinely done, for example,
in the Ames test for mutagenicity. How-
ever, even these preparations need to be
carefully standardized.
The essential step for any battery of in
vitro neurotoxicity tests is their validation.
This process is of utmost importance for
consideration and possible use of in vitro
tests in the regulatory and risk assessment
arena. Validation should establish the sen-
sitivity and specificity ofthe test battery, its
reproducibility among laboratories, and its
degree ofpredictivity ofhuman neurotoxi-
cants. Though a 100% correlation between
in vitro and in vivo end points would be
difficult to achieve (as even animal tests are
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not 100% predictive ofhuman toxicity),
this should be the goal to strive for (11),
notwithstanding the fact that some in vivo
end points (e.g., sensory functions, long-
term memory) do not have in vitro coun-
terparts. The validation process should
require the choice ofa defined test battery
(both in terms of test system and ofend
points) and the testing, under standardized
conditions, ofa large number ofchemicals,
some ofwhich are neurotoxic (albeit with
different targets and mechanisms ofneuro-
toxicity) and others that are known not to
affect the nervous system. Such a process
would require a well-organized, strictly
controlled, and carefully managed effort
similar to others that have already taken
place (for example, the study of in vitro
alternatives to the Draize test). To date,
however, such multicenter effort has not
been carried out, and the literature pro-
vides only examples ofvalidation efforts in
which few chemicals were tested and differ-
ent test batteries were used (25,26). Such
studies, though interesting and useful, do
not offer sufficient information and confi-
dence for any utilization oftheir results in
the hazard assessment process. They
should, however, be an impetus for larger
efforts to be initiated.
Future Perspectives
One ofthe goals ofin vitro testing for toxi-
cants should be that ofreducing the use of
animals rather then replacing them for tox-
icity testing (27). As such, in vitro tests
should complement current in vivotests, as
it is unlikely that in vitro methodologies
will become a complete alternative to
existing approaches and testing methods.
The efforts to validate a substitute for the
Draize test represent a case in point, as in
vitro alternatives have so far failed to be
better or even equal predictors ofeye irrita-
tion potential as the Draize test itself(12).
The case ofneurotoxicity is as much, ifnot
more, complicated. Major problems related
to the development of in vitro methods for
neurotoxicants are the complexity ofthe
nervous system (both structurally and
functionally) and the multiplicity of
potential targets.
It is highly unlikely that a single test
will be developed for neurotoxicity. The
suggested battery of tests offers some
promise. However, as a screening device,
practicality will necessarily limit the num-
ber of end points that can be measured,
with the ensuing risk ofgenerating poten-
tial false negatives. Before a battery of in
vitro tests can be taken into serious con-
sideration as an alternative, a large valida-
tion study should be carried out; several
laboratories from different countries
should be involved in the testing ofsev-
eral hundred compounds. Such effort,
and the necessary funding, can only come
from a common action of European,
North American, and other regulatory
and scientific agencies, institutions, and
foundations. National and international
agencies and scientific organizations
should promote the formation ofa panel
ofneurotoxicologists and statisticians who
would meet, following a series ofdiscus-
sions and perhaps additional pilot studies,
to define the nature of the battery (cell
types, end points), and oversee the com-
pletion ofthe large validation experiment.
Such a validated in vitro battery could
serve as the basis for prioritization of
chemicals for further in vivo testing.
In the meantime, in vitroapproaches can
be useful as screening tools forparticular sit-
uations or classes ofcompounds. For exam-
ple, cells expressing acetylcholinesterase or
neuropathy target esterase have been used to
screen for the inhibitory potency oforgano-
phosphorus esters and may be useful as pre-
dictors ofacute cholinergic toxicity versus
delayed neurotoxicity (28). As previously
mentioned, in vitro systems are very useful
in studying mechanisms ofneurotoxicity,
and represent an important component of
all stages oftoxicitytesting.
In summary, it is tempting to conclude
that neurotoxicology does not offer much
promise in terms of the development of
alternatives to the current testing proce-
dures. Certainly, the road may be more dif-
ficult than for other, less complex, target
organs. However, a large concerted effort
to launch the validation process, and to go
beyond the necessarily incomplete and
fragmented attempts so far, would be of
great benefit. With the results of such
efforts in hand, the scientific and regula-
tory communities would be able to decide
whether sufficient confidence can be placed
in such an alternative approach and to
define its role in a concerted testing strat-
egy, or whether in vitro tests should be
confined for use in specific situations or in
mechanistic studies in neurotoxicology.
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